Vaccines for preventing malaria (blood-stage) (Q21032518)

2 July 2019

meta-analysis

0 references

review article

1 reference

title

Vaccines for preventing malaria (blood-stage) (English)

1 reference

2 July 2019

0 references

1 reference

1 reference

2

H Gelband

H

Gelband

1 reference

27 July 2022

1

P Graves

P

Graves

1 reference

27 July 2022

language of work or name

English

0 references

publication date

18 October 2006

1 reference

2 July 2019

Cochrane Database of Systematic Reviews

published in

1 reference

2 July 2019

page(s)

CD006199

1 reference

2 July 2019

issue

4

1 reference

2 July 2019

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Strain-specific humoral response to a polymorphic malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Antibody and clinical responses in volunteers to immunization with malaria peptide-diptheria toxoid conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Vaccines for preventing malaria (SPf66)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Vaccines for preventing malaria (pre-erythrocytic)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

The global distribution and population at risk of malaria: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Progress and challenges for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

The global distribution of clinical episodes of Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Vaccines for preventing malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006199

Malaria vaccine developments

21 January 2018

1 reference

12 December 2020

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

1 reference

12 December 2020

Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk?

1 reference

12 December 2020

Update on the clinical development of candidate malaria vaccines.

1 reference

12 December 2020

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

1 reference

12 December 2020

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

1 reference

12 December 2020

Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.

1 reference

12 December 2020

[NANP]19-5.1. A malaria vaccine field trial in Nigerian children.

1 reference

12 December 2020

10.1002/14651858.CD006199

Identifiers

DOI

1 reference

2 July 2019

PMCID

6532641

1 reference

2 July 2019

PubMed ID

17054281

1 reference

2 July 2019